Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors), uPAR inhibitors(Urokinase plasminogen activator surface receptor inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC32H35NO13 |
InChIKeySLURUCSFDHKXFR-WWMWMSKMSA-N |
CAS Registry202350-68-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Ductal Adenocarcinoma | Preclinical | Denmark | 17 Jan 2025 | |
Pancreatic Ductal Adenocarcinoma | Preclinical | Denmark | 17 Jan 2025 |